Hemostasis disorders in patients with systemic AL-amyloidosis

Cover Page

Cite item

Full Text

Abstract

Aim. To analyze the frequency and nature of hemorrhagic and thrombotic complications in patients with systemic AL-amyloidosis and compare with laboratory changes in the hemostasis system.

Materials and methods. The prospective study included 40 patients with newly diagnosed AL-amyloidosis. To detect amyloid, all patients underwent bone marrow trephine biopsy and duodenal biopsy, and 28 (70%) patients underwent biopsy of the affected organ. Before the start of therapy, all patients were determined the platelet count, activated partial thromboplastin time, thrombin time, fibrinogen concentration, time of XIIa-dependent fibrinolysis, antithrombin III, D-dimer, activity of blood coagulation factors VIII, X and vWF. The statistical part of the study was carried out using the IBM SPSS Statistics 2017 system software (SPSS, Chicago, IL, USA).

Results. In 20 (50%) patients, hemorrhages on the skin and mucous membranes were diagnosed as vascular purpura. Before the start of therapy, 7 (17.5%) patients had thrombosis, including leg vein thrombosis (5 patients), ischemic stroke (2 patients). There was a direct correlation between thrombotic complications and cutaneous hemorrhagic syndrome (p=0.007). In 15 (75%) cases, cutaneous hemorrhagic syndrome was accompanied by hypercoagulable shifts in the hemostasis system. Of the 20 patients with cutaneous hemorrhagic syndrome, 19 (95%) patients had kidney damage, including 15 patients with nephrotic syndrome. Hematoma type of bleeding, as well as heavy bleeding was not observed, including after a biopsy of the internal organs. According to the totality of hemostasis indicators, hypercoagulation syndrome was more often observed (in 23; 56% of patients). Hypocoagulation was diagnosed only in 2 (5%) patients with liver damage, 16 (39%) patients had normocoagulation.

Conclusion. Cutaneous hemorrhagic syndrome is the most common clinical manifestation of disorders in the hemostasis system in patients with AL-amyloidosis. The relationship of hemorrhages on the skin with nephrotic syndrome has been established, which may indicate a single pathogenetic mechanism. Cutaneous hemorrhagic syndrome is associated with hypercoagulable shifts in hemostasis and a high risk of thrombotic complications.

About the authors

Irina G. Rekhtina

National Medical Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-5440-4340

Doctor of Medical Sciences, Head. department of chemotherapy of plasma cell dyscrasias

Russian Federation, Moscow

Victoria A. Khyshova

National Medical Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-1008-5007

postgraduate student, hematologist, department of chemotherapy of plasma cell dyscrasias

Russian Federation, Moscow

Nadezhda I. Zozulya

National Medical Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0001-7074-0926

Doctor of Medical Sciences, Head. dept. coagulopathies

Russian Federation, Moscow

Valentina N. Dvirnyk

National Medical Research Center for Hematology

Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-9877-0796

Candidate of Medical Sciences, Head. centralized clinical diagnostic laboratory

Russian Federation, Moscow

Larisa P. Mendeleyeva

National Medical Research Center for Hematology

Author for correspondence.
Email: viktoria2102@icloud.com
ORCID iD: 0000-0002-4966-8146

Doctor of Medical Sciences, Professor, Head of the Department for Scientific and Educational Work, Head. dept. chemotherapy for paraproteinemic hemoblastoses

Russian Federation, Moscow

References

  1. Muchtar E, Gertz MA, Kyle RA, et al. A Modern Primer on Light Chain Amyloidosis in 592 Patients With Mass Spectrometry – Verified Typing. Mayo Clin Proc. 2019;94(3):472-83. doi: 10.1016/j.mayocp.2018.08.006
  2. Yood RA, Skinner M, Rubinow A, Talarico L. CAS. Bleeding manifestations in 100 patients with amyloidosis. J Am Med Assoc. 1983;10(249):1922-324.
  3. Eder L, Bitterman H. Amyloid Purpura. N Engl J Med. 2007;356(23):2406. doi: 10.1056/nejmicm061510
  4. Wechalekar AD, Gillmore JD, Bird J, et al. Guidelines on the management of AL amyloidosis. Br J Haematol. 2015;168(2):186-206. doi: 10.1111/bjh.13155
  5. Stoopler ET, Alawi F, Laudenbach JM, Sollecito TP. Bullous amyloidosis of the oral cavity: A rare clinical presentation and review. Oral Surgery, Oral Med Oral Pathol Oral Radiol Endodontology. 2006;101(6):734-40. doi: 10.1016/j.tripleo.2006.01.003
  6. Abdallah N, Muchtar E, Dispenzieri A, et al. Coagulation Abnormalities in Light Chain Amyloidosis. Mayo Clin Proc. 2021;96(2):377-87. doi: 10.1016/j.mayocp.2020.06.061
  7. Patel G, Hari P, Szabo A, et al. Acquired factor X deficiency in light-chain (AL) amyloidosis is rare and associated with advanced disease. Hematol Oncol Stem Cell Ther. 2019;12(1):10-4. doi: 10.1016/j.hemonc.2018.05.002
  8. Nguyen AL, Kamal M, Raghavan R, Nagaraj G. Acquired factor VII deficiency causing severe bleeding disorder secondary to AL amyloidosis of the liver. Hematol Rep. 2018;10(3). doi: 10.4081/hr.2018.7235
  9. Emori Y, Sakugawa M, Niiya K, et al. Life-threatening bleeding and acquired factor V deficiency associated with primary systemic amyloidosis. Blood Coagul Fibrinolysis. 2002;13(6):555-9. doi: 10.1097/00001721-200209000-00011
  10. Wiest R, Klouche M, Härle P, et al. Acquired combined factor X and XII deficiency with isolated bleeding complications in a patient with AL amyloidosis. Ann Hematol. 2005;84(3):196-9. doi: 10.1007/s00277-004-0970-8
  11. Gamba G, Montani N, Anesi E, et al. Clotting alterations in primary systemic amyloidosis. Haematologica. 2000;85(3):289-92.
  12. Uchiba M, Imamura T, Hata H, et al. Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid. 2009;16(2):89-93. doi: 10.1080/13506120902879269
  13. Pudusseri A, Sanchorawala V, Sloan JM, et al. Prevalence and prognostic value of D-dimer elevation in patients with AL amyloidosis. Am J Hematol. 2019;94(10):1098-103. doi: 10.1002/ajh.25576
  14. Migrino RQ, Hari P, Gutterman DD, et al. Systemic and microvascular oxidative stress induced by light chain amyloidosis. Int J Cardiol. 2010;145(1):67-8. doi: 10.1016/j.ijcard.2009.04.044
  15. Gertz MA, Kyle RA. Hepatic amyloidosis (Primary [AL], immunoglobulin light chain): The natural history in 80 patients. Am J Med. 1988;85(1):73-80. doi: 10.1016/0002-9343(88)90505-0
  16. Park MA, Mueller PS, Kyle RA, et al. Primary (AL) hepatic amyloidosis: Clinical features and natural history in 98 patients. Medicine (Baltimore). 2003;82(5):291-8. doi: 10.1097/01.md.0000091183.93122.c7
  17. Kujawski B, Johnson D, Radadia K, et al. An Uncommon Presentation of Amyloidosis. Med Forum. 2015;15(1):8-11. doi: 10.29046/tmf.015.1.004
  18. Kerlin BA, Ayoob R, Smoyer WE. Epidemiology and pathophysiology of nephrotic syndrome-associated thromboembolic disease. Clin J Am Soc Nephrol. 2012;7(3):513-20. doi: 10.2215/CJN.10131011
  19. Berghoff M, Kathpal M, Khan F, et al. Endothelial dysfunction precedes C-fiber abnormalities in primary (AL) amyloidosis. Ann Neurol. 2003;53(6):725-30. doi: 10.1002/ana.10552
  20. Bright M, Truran S, Schlundt B, Gutterman DD. Endothelium-Independent Microvascular Dysfunction Induced by AL Amyloidosis Light Chains in Human Adipose Arterioles: Novel Mechanism of Amyloid Injury. Annu Sci Meet. 2009;13:178.
  21. Kastritis E, Papassotiriou I, Terpos E, et al. Clinical and prognostic significance of serum levels of von Willebrand factor and ADAMTS-13 antigens in AL amyloidosis. Blood. 2016;128(3):405-9. doi: 10.1182/blood-2016-02-702696
  22. Palladini G, Hegenbart U, Milani P, et al. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014;124(15):2325-32. doi: 10.1182/blood-2014-04-570010
  23. Palladini G, Merlini G. What is new in diagnosis and management of light chain amyloidosis? Blood. 2016;128(2):159-68. doi: 10.1182/blood-2016-01-629790
  24. Perfetti V, Palladini G, Casarini S, et al. The repertoire of λ light chains causing predominant amyloid heart involvement and identification of a preferentially involved germline gene, IGLV1-44. Blood. 2012;119(1):144-50. doi: 10.1182/blood-2011-05-355784
  25. Abraham RS, Geyer SM, Price-Troska TL, et al. Immunoglobulin light chain variable (V) region genes influence clinical presentation and outcome in light chain-associated amyloidosis (AL). Blood. 2003;101(10):3801-8. doi: 10.1182/blood-2002-09-2707
  26. Choufani EB, Sanchorawala V, Ernst T, et al. Acquired factor X deficiency in patients with amyloid light-chain amyloidosis: Incidence, bleeding manifestations, and response to high-dose chemotherapy. Blood. 2001;97(6):1885-7. doi: 10.1182/blood.V97.6.1885
  27. Cordes S, Gertz MA, Buadi FK, et al. Autologous stem cell transplantation in immunoglobulin light chain amyloidosis with factor X deficiency. Blood Coagul Fibrinolysis. 2016;27(1):101-8. doi: 10.1097/MBC.0000000000000367
  28. Bever KM, Masha LI, Sun F, et al. Risk factors for venous thromboembolism in immunoglobulin light chain amyloidosis. Haematologica. 2016;101(1):86-90. doi: 10.3324/haematol.2015.133900
  29. Freeman B, Sloan JM, Seldin DC, et al. Multiple arterial and venous thromboembolic complications in AL amyloidosis and cardiac involvement: A case report and literature review. Amyloid. 2012;19(3):156-60. doi: 10.3109/13506129.2012.694825
  30. Glassock RJ. Prophylactic anticoagulation in nephrotic syndrome: A clinical conundrum. J Am Soc Nephrol. 2007;18(8):2221-5. doi: 10.1681/ASN.2006111300
  31. January CT, Wann LS, Calkins H, et al. Guideline for the Management of Patients With Atrial Fibrillation. Circulation. 2019;140:e125-51. doi: 10.1161/CIR.0000000000000665

Copyright (c) 2023 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies